Before instituting Brozil therapy, every attempt should be made to controls serum lipids with appropriate diet, exercise, weight loss in obese patients and to control other medical problems, eg diabetes mellitus and hypothyroidism.
Pre-treatment laboratory studies should be performed to ensure that patients have abnormal levels of serum lipids. Periodic determination of serum levels should be obtained during administration. Gemfibrozil should be withdrawn after 3 months if the lipid response is inadequate.
Brozil capsule should be used with caution in patients with impaired hepatic function.
Brozil capsule should be used with caution in patients with impaired severe renal function. Reduced clearance leads to increased incidence of side effects; reduced dosage is recommended.
Use in pregnancy & lactation: Safety in pregnancy and nursing mothers have not been established. Therefore, it should not be used in pregnant women unless potential benefit justifies the potential risk to the fetus.
Mothers taking gemfibrozil should not breastfeed.
Use in children: Safety and efficacy in children have not been established.